Palatin Technologies (NYSEAMERICAN:PTN) said it is prioritizing development of next-generation melanocortin-4 receptor, or MC4R, agonists for rare and syndromic obesity disorders, while also seeking additional financing to support its programs and address a going-concern uncertainty disclosed alongside fiscal 2026 results.
President and Chief Executive Officer Carl Spana said the company is initially targeting hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. Palatin’s objective is to develop therapies with meaningful efficacy, improved gastrointestinal tolerability and little to no hyperpigmentation for long-term use.
Three MC4R Development Approaches
The company is advancing two peptide series: non-lipidated PL1000 compounds and lipidated PL2000 compounds. According to Palatin, tested compounds in both series have shown potent MC4R agonism without MC1R agonism. In preclinical diet-induced obese mouse models, compounds from both series produced dose-dependent reductions in food intake and body weight.
Palatin has established the feasibility of once-weekly subcutaneous dosing for its lead non-lipidated peptide candidate and is working on a controlled-release formulation. Its lipidated peptide candidate has also demonstrated reduced food intake and weight loss with once-weekly dosing in mice, with preclinical pharmacokinetic data supporting the possibility of less-frequent dosing in humans.
During the question-and-answer session, Spana said the lipidated approach is the company’s preferred route because the molecule’s lipid component binds to a plasma protein, giving it longer duration without relying on a polymer formulation. He said the approach may offer greater flexibility for dose titration and a less bulky injection profile.
Still, Palatin plans to continue the lipidated and non-lipidated programs in parallel for now. Spana said the company would likely slow development of the polymer-based, non-lipidated approach if the lipidated candidate shows efficacy in the clinic, rather than advancing both through Phase II studies.
Palatin is conducting work needed to submit an investigational new drug application for the lipidated candidate. Spana said the principal remaining work is initial animal toxicology studies, alongside continuing manufacturing efforts. Subject to funding, the company is targeting Phase I single-ascending-dose and multiple-ascending-dose studies in the first half of calendar 2027, with data expected in the second half of that year.
The company also is developing oral MC4R agonists, drawing on lessons from its earlier PL7737 candidate and using artificial intelligence and machine-learning tools. Spana said Palatin identified multiple scaffolds with improved potency and selectivity and is working to select a compound by year-end and begin IND-enabling studies. The company is targeting initiation of oral Phase I studies in the second half of 2027, subject to funding, with initial data expected in the first half of 2028.
Clinical and Indication Plans
Spana said Palatin expects its Phase I multiple-ascending-dose studies to enroll healthy obese participants for 28 days. The company intends to evaluate safety, tolerability, pharmacokinetics, food intake and weight-loss effects in those studies.
Hypothalamic obesity is expected to be the first indication pursued, according to Spana, followed closely by Prader-Willi syndrome, potentially in parallel depending on available resources. Bardet-Biedl syndrome would be the third planned indication.
On gastrointestinal tolerability, Spana said one strategy is to avoid high drug exposure associated with bolus dosing by maintaining drug concentrations within a therapeutic range. He said lipidated peptides may help flatten absorption and reduce certain adverse events, although some effects may be inherent to MC4R activation.
Collaboration Revenue and Non-Core Assets
Beyond obesity, Palatin cited its August 2025 retinal disease research collaboration and license agreement with Boehringer Ingelheim. The company said Boehringer Ingelheim has paid aggregate upfront and initial milestone amounts of €7.5 million, with the agreement providing up to €280 million in additional success-based milestones and tiered royalties. Palatin continues to conduct reimbursed research under the arrangement.
The company also sublicensed its PL9643 dry-eye program to Altanispac Labs. Palatin said it is pursuing partnerships for non-core assets, including its PL8177 ulcerative colitis program, which has positive Phase II proof-of-principle findings, and its diabetic nephropathy program, which has encouraging open-label Phase II data.
Chief Operating Officer and Chief Financial Officer Steve Wills said Palatin expects to receive an achieved milestone from Boehringer Ingelheim within the next two to three quarters. He also said the company has interest in its ulcerative colitis program, other ocular indications, and MC1R autoimmune and anti-inflammatory opportunities, though he did not provide a timeline for potential agreements.
Fiscal 2026 Results and Liquidity
For the fiscal year ended June 30, 2026, Palatin reported collaboration and license revenue of $13.2 million, compared with no revenue in fiscal 2025. The total included $9.4 million related to the Boehringer Ingelheim collaboration and $3.8 million related to the Altanispac sublicense, recognized as non-cash debt cancellation.
- Fiscal 2026 net loss was $8.4 million, or $2.96 per basic and diluted share, compared with a net loss of $17.3 million, or $32.15 per share, in fiscal 2025.
- Total operating expenses were $21.9 million, compared with $17.5 million a year earlier.
- Research and development expense declined to $12.4 million from $14.9 million, while general and administrative expense rose to $9.5 million from $7.8 million.
- Net cash used in operating activities was $13.5 million, compared with $21.3 million in fiscal 2025.
- Palatin ended the fiscal year with $7.5 million in cash and cash equivalents and $1.8 million in current liabilities.
Wills said management does not expect existing cash to fund operations for at least 12 months after issuance of the company’s financial statements, resulting in substantial doubt about Palatin’s ability to continue as a going concern. The company said it will need additional financing through equity offerings, collaborations or other sources of capital.
Wills also said exercise of the Series J warrants issued in the company’s November 2025 financing could generate approximately $18.5 million if exercised in full. The warrants are triggered by the earlier of 18 months or an IND filing for one of Palatin’s internal obesity MC4R compounds.
About Palatin Technologies (NYSEAMERICAN:PTN)
Palatin Technologies, Inc is a biopharmaceutical company focused on developing medicines that target melanocortin receptors, a group of receptors involved in regulating sexual function, inflammation, metabolism and other biological processes. The company’s approach uses synthetic peptide therapeutics designed to selectively activate or modulate these receptors.
Palatin’s most advanced product is Vyleesi (bremelanotide), an injectable melanocortin receptor agonist approved in the United States for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women.
